Progresión fisiopatológica e impacto funcional sistémico de la aterosclerosis subclínica

Un análisis del curso de la vida desde la juventud hasta la mitad de la vida

Resumen

Aterosclerótico enfermedad cardiovascular (ASCVD) sigue siendo la principal causa de mortalidad en todo el mundo, y sus manifestaciones clínicas representan la culminación en etapa tardía de una trayectoria biológica que comienza décadas antes —a menudo en la vida fetal y sin duda en la segunda década—. Esta revisión integra la biología vascular estructural, la hemodinámica, la causalidad lipídica, inflamación, fenotipos específicos de sexo, neurodegeneración y reversibilidad del estilo de vida en un marco unificado para comprender ateroesclerosis subclínica como una enfermedad activa, progresiva y modificable. Examinamos la heterogeneidad regional en la arquitectura de la pared arterial y el papel de vasa vasorum, la divergencia de las grandes arterias ateroesclerosis de la enfermedad de pequeños vasos cerebrales, los determinantes hemodinámicos de placa la localización y la evidencia longitudinal de Día de pago, Bogalusa, CARDIA, MESA, y la serie fetal FELIC que anclan el inicio de la enfermedad en la vida temprana. Sintetizamos evidencia de aleatorización mendeliana, genética de poblaciones y ensayos de intervención que establecen apolipoproteína que contiene b lipoproteínas como el impulsor causal necesario de aterogénesis, y situamos a la Lp(a), la inflamación, la hematopoyesis clonal, disfunción endotelial, rarefacción microvascular y rigidez arterial dentro de este marco. Concluimos con las imágenes y biomarcador herramientas que permiten la detección durante la ventana preclínica prolongada, los fenotipos específicos de sexo que históricamente han sido poco reconocidos y la evidencia de los ensayos, más prominentemente la Ensayo sobre el estilo de vida y el corazón, la serie de casos de Esselstyn, STARS y el documentado por IVUS estatinas y ensayos de regresión con inhibidores de PCSK9 (REVERSIÓN, ASTEROIDE, Saturno, GLAGOV, PACMAN-AMI, Huygens) — lo que respalda la conclusión de que la aterosclerosis subclínica es, cuando se aborda de forma temprana y agresiva, una enfermedad reversible.

Palabras clave

Aterosclerosis subclínica; apolipoproteína B; lipoproteína(a); disfunción endotelial; vasa vasorum; enfermedad de pequeños vasos cerebrales; coronario arteria calcio; velocidad de onda de pulso; regresión de la placa; alimento integral dieta basada en plantas.

1. Introducción

La aparición de la ECVA clínica es la culminación de una trayectoria biológica silenciosa y de múltiples décadas que a menudo comienza en la segunda década de la vida —y en el caso de los fetos expuestos a una madre hipercolesterolemia, incluso antes del nacimiento. La aterosclerosis subclínica se refiere a la presencia de alteraciones estructurales en la pared arterial —incluyendo engrosamiento intimal, la retención de lipoproteínas, la acumulación de células espumosas y la formación temprana de placas, que preceden a las manifestaciones sintomáticas evidentes como angina, infarto de miocardio, infarto isquémico, claudicación periférica o demencia vascular. Esta progresión silenciosa está gobernada por una interacción estrechamente acoplada entre fuerzas hemodinámicas, variaciones estructurales en la pared arterial, el flujo de lipoproteínas, la activación inmunitaria y el estrés metabólico.

Aunque tradicionalmente se ha enmarcado como una enfermedad de la senescencia, los estudios de cohortes longitudinales y los datos de autopsias han cambiado fundamentalmente el enfoque hacia los adultos jóvenes y los adolescentes, revelando que sutiles déficits funcionales cotidianos —que van desde una velocidad de procesamiento cognitivo disminuida hasta una reserva renal y eréctil alterada— surgen mucho antes de que se alcancen los umbrales clínicos tradicionales para el diagnóstico. La formulación más rigurosa de este concepto a lo largo de la vida es la de exposición acumulativa o “años de colesterol” modelo, en el cual la integral de la concentración de partículas de apoB plasmática a lo largo del tiempo predice tanto el momento como la gravedad de los eventos clínicos [7], [9].

Esta revisión ofrece una síntesis exhaustiva de la fisiopatología, la distribución anatómica y las consecuencias funcionales de la enfermedad vascular subclínica en todo el árbol arterial humano, prestando especial atención a (i) la biología divergente de la aterosclerosis de grandes arterias y la enfermedad de pequeños vasos cerebrales; (ii) la centralidad causal de las lipoproteínas que contienen apoB y la contribución de la Lp(a), la inflamación y la hematopoyesis clonal; (iii) los fenotipos específicos de cada sexo; (iv) las modalidades de detección emergentes; y (v) la evidencia basada en ensayos clínicos de que la enfermedad subclínica es reversible cuando se aborda de forma temprana y agresiva.

2. Las lipoproteínas que contienen apolipoproteína B como el factor causal necesario

2.1 La síntesis de aleatorización mendeliana

Aleatorización mendeliana (MR) proporciona una de las formas más rigurosas de inferencia causal disponibles fuera ensayos controlados aleatorizados. Al explotar la asignación aleatoria de alelos en la concepción, los estudios RM estiman el efecto de por vida de una exposición determinada genéticamente sin la confusión de causalidad inversa, covariables de estilo de vida o error de medición. Ference y sus colegas analizaron 50 polimorfismos en nueve genes relacionados con las LDL en 312 321 participantes y establecieron que cada disminución genética de 1 mmol/L (≈38.7 mg/dL) en el c-LDL confiere un riesgo relativo reducción de aproximadamente el 54.5 por ciento para enfermedad coronaria — un efecto aproximadamente tres veces mayor por unidad LDL que el de las estatinas iniciadas en la mediana edad1].

El relación dosis-respuesta es loglineal sin un umbral detectable, lo que respalda un modelo de exposición acumulativa. Un segundo estudio de RM que utiliza polimorfismos en PCSK9, HMGCR, y NPC1L1 demostró que la reducción del riesgo guarda una estrecha correlación con la magnitud y la duración de la reducción del c-LDL, lo que respalda la conclusión de que la exposición acumulada a lo largo de la vida a las lipoproteínas que contienen apoB es un determinante central de la aterogénesis, mientras que la vía molecular específica a través de la cual se reduce el c-LDL es menos importante para la reducción del riesgo de ECVA [3]. Una Declaración de Consenso de la Sociedad Europea de Ateroesclerosis de 2017 analizó más de 200 estudios genéticos, epidemiológicos prospectivos y de intervención aleatorizados, y concluyó que el LDL cumple con el Criterios de Bradford Hill para la causalidad en la ECVAS4], y la actualización de la EAS de 2020 extendió esta conclusión a las lipoproteínas que contienen apoB en general [19].

2.2 La ApoB como la partícula unificadora

Cada partícula de lipoproteína aterogénica importante — VLDL, IDL, LDL, Lp(a) y quilomicrón remanentes — transportan una sola molécula de apolipoproteína B: apoB-100 para partículas de origen hepático y apoB-48 para restos intestinales. ApoB por lo tanto cuenta partículas aterogénicas, mientras que el C-LDL mide una carga cuya proporción respecto al transportador varía con el estado metabólico. En el UK Biobank análisis de 389,529 participantes, la apoB fue el predictor dominante de infarto de miocardio; el c-LDL y el c-no-HDL perdieron significancia estadística tras el ajuste por apoB5]. En estados de discordancia — donde el c-LDL es normal pero el número de partículas es alto, como en síndrome metabólico y resistencia a la insulina — la apoB devela un riesgo aterogénico sustancial que una estrategia basada únicamente en el c-LDL pasaría por alto6].

2.3 Exposición acumulada y el concepto de “colesterol-años”

El modelo de exposición acumulativa trata el riesgo de ASCVD como una función de la integral de la concentración plasmática de c-LDL a lo largo del tiempo, análogo a “paquetes-año”para el tabaco. Varios análisis respaldan una relación de dosis-tiempo entre la exposición al C-LDL y los eventos de ECVA. El “umbral” para la enfermedad clínicamente aparente en hombres se ha descrito en algunos análisis como aproximadamente 5,000 mg/dL·años —por ejemplo, LDL de 125 mg/dL × 40 años, lo que corresponde a una edad de ~50 años en las poblaciones occidentales modernas—, pero el valor exacto de LDL-año en el cual surge la enfermedad clínica depende del modelo y debe presentarse como ilustrativo en lugar de como un límite biológico universal [7], [9].

El “LDL años placa”el marco reformula la prevención cuantitativamente en torno a la carga acumulativa. Por ejemplo, un LDL de por vida de 70 mg/dL × 80 años produce ≈5,600 mg/dL·años; un LDL de 130 mg/dL × 50 años produce ≈6,500 mg/dL·años; y la heterocigota no tratada hipercolesterolemia familiar los pacientes con LDL de 250 mg/dL superan los umbrales ilustrativos comunes a principios de los treinta años. Estos cálculos son útiles para comunicar la biología de dosis y tiempo y para explicar por qué la HF heterocigota no tratada conlleva un alto riesgo de cardiopatía coronaria durante toda la vida, pero no deben presentarse como umbrales de riesgo individual validados7], [8], [9].

Categoría	Exposición acumulativa a las LDL	Trayectoria aproximada	Riesgo ilustrativo de cardiopatía coronaria a lo largo de la vida
Bajo	<5,000 mg/dL·año	LDL 70 × 70 años	<5%
Intermedio	5,000–8,000 mg/dL·año	LDL 100 × 60 años	10–20%
Alto	8,000–12,000 mg/dL·año	LDL 130 × 65 años	30–50%
Muy alto	>12,000 mg/dL·año	LDL 190 × 65 años (HeFH)	>50% a los 60 años

Tabla 1. Categorías ilustrativas de exposición acumulada al colesterol LDL y riesgo aproximado de cardiopatía coronaria a lo largo de la vida. Adaptado de Ference et al. y Domanski et al.7], [8], [9]. Estas categorías son ayudas de comunicación ilustrativas, no umbrales de riesgo individual validados por guías clínicas.

2.4 Tsimane y Hadza: El experimento natural de un LDL bajo durante toda la vida

Kaplan y sus colegas examinaron las puntuaciones de CAC en 705 Tsimane recolectores-horticultores de la Amazonía boliviana de entre 40 y 94 años. El C-LDL medio fue de 91 mg/dL, y el 85 por ciento de los adultos de 40 años o más tenían un CAC de cero, en comparación con aproximadamente el 50 por ciento de los adultos estadounidenses de edad similar en MESA. El sesenta y cinco por ciento de los mayores de 75 años tenían un CAC de cero —el nivel más bajo de aterosclerosis coronaria jamás medido en ninguna población— y solo el 8 por ciento tenía un CAC ≥100, frente a más del 50 por ciento en poblaciones estadounidenses de la misma edad [10].

Este experimento natural respalda la conclusión de que mantener un C-LDL relativamente bajo a lo largo de la vida, combinado con una alta actividad física y un mínimo fumar, se asocia con una prevalencia muy baja de enfermedad coronaria calcificación. No debe plantearse como una prueba de que el c-LDL ≤90 mg/dL elimina prácticamente la aterosclerosis coronaria, ya que el fenotipo de los tsimanes refleja múltiples exposiciones a lo largo de la vida y no el c-LDL de forma aislada. Se ha descrito a los hadza de Tanzania como una población de cazadores-recolectores físicamente activa con características cardiometabólicas favorables en los estudios disponibles, pero no se han realizado imágenes directas de CAC en este grupo; por lo tanto, las conclusiones sobre la ausencia de enfermedad coronaria clínica en los hadza son inferenciales en lugar de directas [11].

2.5 Niveles bajos de LDL genéticos de por vida: PCSK9 y ANGPTL3

Cohen y sus colegas identificaron mutaciones naturales de pérdida de función en PCSK9 (R46L, Y142X, C679X) que reducen el LDL entre un 15 y un 40 por ciento a lo largo de la vida. Los portadores de variantes seleccionadas mostraron reducciones importantes en los eventos de cardiopatía coronaria, y las estimaciones más llamativas —incluidas reducciones cercanas al 88 por ciento para algunas variantes— reflejan tamaños del efecto que varían según la variante y la ascendencia12]. Tales tamaños del efecto superan con creces lo que cualquier intervención farmacológica iniciada en la mitad de la vida puede lograr. De manera similar, las variantes homocigóticas de pérdida de función en ANGPTL3 producir hipobetalipoproteinemia con LDL muy baja y triglicéridos; las series epidemiológicas describen un riesgo de ASCVD notablemente reducido y favorable perfiles lipídicos en dichos portadores, aunque las tasas de eventos no se han cuantificado en cohortes aleatorizadas13].

Estos experimentos genéticos establecen una condición de contorno útil: cuando la carga de partículas de apoB durante toda la vida es genéticamente baja, la aterosclerosis aparece marcadamente suprimida incluso sin intervención farmacológica. El mimetismo farmacológico de estos fenotipos —a través de anticuerpos monoclonales contra PCSK9, agentes de ARNsi e inhibidores de ANGPTL3— ha demostrado una reducción aditiva de eventos además de la terapia con estatinas. Los análisis de Fourier y la extensión abierta FOURIER respalda tasas de eventos progresivamente más bajas entre los pacientes que alcanzan niveles muy bajos de LDL, incluidos LDL <20 mg/dL, sin una señal de seguridad excesiva durante el seguimiento disponible18].

2.6 Por qué un LDL muy bajo y sostenido reduce notablemente la aterogénesis

Endotelial transcitosis de LDL en el íntima depende de la concentración, y la retención mediada por proteoglicanos —el paradigma de respuesta a la retención de Tabas, Williams y Borén— se vuelve menos probable a medida que disminuye el flujo de partículas de apoB83]. Los recién nacidos tienen un C-LDL de ≈30 mg/dL, y la ateroesclerosis lesiones no se detectan típicamente en esta etapa; esto debe interpretarse como evidencia de que un C-LDL de por vida muy bajo es incompatible con las etapas iniciales de la aterogénesis a escala poblacional, en lugar de como una afirmación de que la aterogénesis sea biológicamente imposible a cualquier valor único de C-LDL. Las cohortes con C-LDL de por vida <70 mg/dL (pérdida de función de PCSK9, pérdida de función de ANGPTL3, HF tratada) demuestran reducciones notables en las tasas de eventos, con regresión de la placa documentada por IVUS con un C-LDL durante el tratamiento <60 mg/dL en los ensayos REVERSAL, ASTEROID, SATURN y GLAGOV [14], [15], [16], [17].

FOURIER-OLE extendido evolocumab seguimiento durante una mediana de aproximadamente 5 años e informó una reducción continua de eventos con un c-LDL durante el tratamiento <20 mg/dL sin señales de seguridad adicionales durante el seguimiento disponible18]. Una demostración formal de dosis-respuesta sin que se haya establecido firmemente una meseta a estos niveles muy bajos de LDL, los datos disponibles son consistentes con un beneficio continuo y ninguna toxicidad compensatoria hasta el nivel de LDL más bajo alcanzado hasta la fecha en las poblaciones de los ensayos.

2.7 Reconocimiento y refutación de la postura de los escépticos de las LDL

Un pequeño grupo de autores —de forma más destacada Ravnskov, Diamond y Kendrick— han argumentado que el LDL no es causal, citando estudios observacionales en poblaciones de edad avanzada en los que el LDL parece no ser predictivo (el llamado “paradoja lipídica”). Las refutaciones estándar están bien establecidas. Primero, la causalidad inversa predomina en la vejez: la enfermedad crónica, la malabsorción y la fragilidad reducen el c-LDL, sesgando la asociación entre el c-LDL y la mortalidad en los análisis transversales. Segundo, sesgo de supervivencia selecciona a individuos genéticamente protegidos entre aquellos que alcanzan la edad de 80 años con LDL alto. Tercero, la atenuación del riesgo relativo con la edad no implica la atenuación de riesgo absoluto; la tasa de eventos absolutos aumenta dramáticamente con la edad. Cuarto, la evidencia genética y farmacológica es mutuamente corroborativa en aproximadamente veinte líneas independientes de investigación, satisfaciendo los criterios de triangulación para la causalidad [4], [6], [19La postura escéptica se basa casi por completo en datos observacionales mientras ignora la evidencia convergente de la genética y de los ensayos aleatorizados.

3. Determinantes estructurales y el papel de los vasa vasorum en la aterogénesis

3.1 Profundidad crítica y la unidad lamelar

En las arterias sistémicas de gran calibre, las demandas metabólicas de la pared gruesa superan la capacidad de difusión simple de oxígeno desde el lumen. La “profundidad crítica” se define como el límite fisiológico de la difusión de oxígeno y nutrientes a partir de la sangre luminal, establecido por Geiringer en aproximadamente 0.5 mm (≈500 μm), o más o menos 29–30 unidades lamelares de la pared medial [78], [79]. Cada unidad laminar consta de una lámina elástica y su capa asociada de células de músculo liso y matriz extracelular, de aproximadamente 15 μm de espesor. Los segmentos de pared más gruesos que este umbral requieren una red microvascular intrínseca —los vasa vasorum— para mantener la viabilidad de la capa media externa y adventicia.

Los vasa vasorum se clasifican en vasa vasorum interna, que se originan directamente de la luz arterial, y vasa vasorum externa, que provienen de ramas distantes y penetran en la adventicia. Las investigaciones de Geiringer establecieron que los vasa vasorum son abundantes en la adventicia y el tercio externo de la media, mientras que los ≈0.5 mm internos (≈30 unidades laminares) de la pared permanecen avasculares y se nutren únicamente mediante difusión luminal.79]. Cuando la pared se engrosa debido a la placa ateroesclerótica o la hiperplasia hipertensiva, la distancia de difusión aumenta, generando un entorno hipóxico en las capas más profundas. La hipoxia desencadena una señalización angiogénica dependiente de HIF-1α, lo que lleva a la proliferación de vasa vasorum que pueden penetrar la lámina elástica interna y entrar en la placa misma, donde sirven tanto como conductos para células inflamatorias como fuentes frágiles de hemorragia intraplaca.

3.2 Nutrición vascular extracraneal vs. intracraneal

La vasculatura intracraneal presenta un perfil arquitectónico único en comparación con la circulación sistémica. Las arterias intracraneales sanas se caracterizan por una túnica media más delgada, una adventicia menos abundante y una relativa escasez de fibras elásticas fibras; muchos carecen de una lámina elástica externa bien definida. Una característica distintiva principal es que los vasos intracraneales están bañados en líquido cefalorraquídeo rico en nutrientes, lo que proporciona soporte metabólico a través de la difusión externa y compensa parcialmente la relativa ausencia de vasa vasorum en las primeras etapas de la vida.

Los estudios modernos de autopsia e imagen han refinado la perspectiva histórica de que los vasa vasorum están ausentes en el cerebro. En una serie de autopsias de 50 casos, se identificaron vasa vasorum en el 72 por ciento de los pacientes, localizados principalmente en la túnica adventicia. Su distribución es marcadamente no uniforme: los vasa vasorum se encuentran con mayor frecuencia en los segmentos proximales —las arterias vertebrales, la arteria basilar y la porción intracraneal de la interna arteria carótida — que en los segmentos distales, como las arterias cerebral media o cerebral anterior. Aunque la aterosclerosis puede ocurrir en ausencia de vasa vasorum, su desarrollo está fuertemente asociado con la progresión de la enfermedad intracraneal: en la arteria vertebral intracraneal, la presencia de vasa vasorum adventiciales se correlaciona con una mayor carga de placa, una calcificación intraplaca más densa y una estenosis luminal más severa estenosis.

Tipo de embarcación	Espesor de pared	Vasa vasorum (etapa temprana)	Fuente nutricional
Aorta / sistémico grande	>1.0 mm (frecuentemente 1.5–2.0 mm)	Abundante en la adventicia y la media externa	Difusión luminal + VV
carótida extracraneal	≈0,6–1,0 mm	Presente en la adventicia	Difusión luminal + VV
ACI / AV intracraneal	≈0.2–0.3 mm	Escasos; principalmente segmentos proximales	Difusión luminal + LCR
ACM / ACA distal	<0.2 mm; carece de LME	Ausente o raro	Difusión luminal + LCR
Arteriolas penetrantes	de 40 a 200 μm de diámetro	Ausente	difusión luminal + líquido intersticial

Tabla 2. Arquitectura comparativa del grosor de la pared arterial, la densidad de los vasa vasorum y la fuente nutricional en las circulaciones sistémica y cerebral. EEL, lámina elástica externa; ICA, arteria carótida interna; VA, arteria vertebral; MCA, arteria cerebral media; ACA, arteria cerebral anterior; VV, vasa vasorum; CSF, líquido cefalorraquídeo.

4. Fuerzas hemodinámicas y localización de la placa

4.1 Esfuerzo cortante laminar frente a perturbado

La naturaleza focal de la aterosclerosis está dictada por la interacción entre el flujo sanguíneo y la geometría arterial. El endotelio sirve como mecanosensor, traduciendo el estrés físico en señalización biológica a través de los cilios primarios, las integrinas y el medio mediado por el glucocálix mecanotransducción, y canales iónicos (especialmente Piezo1 y TRPV4). En los segmentos arteriales rectos, el flujo es laminar, lo que genera un nivel alto y unidireccional esfuerzo cortante en la pared (típicamente de 1 a 7 Pa, o de 10 a 70 dyn/cm²). Este entorno mantiene un fenotipo endotelial aterorresistente caracterizado por la activación sostenida de óxido nítrico sintasa endotelial (eNOS), fosforilación de los factores de transcripción KLF2 y KLF4, y supresión de la señalización de NF-κB, con el resultado de que óxido nítrico la producción es alta, adhesión leucocitaria se suprime y la permeabilidad íntima permanece baja85].

Por el contrario, en los puntos de bifurcación, ramificación y áreas de alta curvatura, el flujo se vuelve “perturbado”. Estas zonas ateropronas experimentan una tensión de corte en la pared promediada en el tiempo baja (a menudo <0.4 Pa) y un alto índice de corte oscilatorio, con la dirección de la fuerza de fricción invirtiéndose durante el ciclo cardíaco. En las regiones de flujo perturbado, el endotelio sufre un cambio fenotípico: las uniones estrechas se aflojan, lo que permite una mayor transcitosis de LDL hacia la íntima; la expresión de VCAM-1, ICAM-1, la E-selectina y la MCP-1 capturan monocitos y linfocitos T circulantes; especies reactivas del oxígeno la generación aumenta a través de la activación de la NADPH oxidasa; y el eje protector KLF2/eNOS es suprimido.

El estudio seminal de dinámica de fluidos computacional realizado por Ku y sus colegas en la bifurcación carotídea humana demostró una estrecha concordancia espacial entre las regiones de bajo cizallamiento y el engrosamiento íntimal, el estudio empírico fundacional de la teoría hemodinámica de la aterogénesis [71]. Este patrón se repite en cada punto de ramificación del árbol arterial: los segmentos proximales de la DA y la CX, el bulbo carotídeo, la bifurcación aórtica abdominal y los ostios de las arterias renales exhiben esta vulnerabilidad dependiente de la geometría.

4.2 Comportamiento celular en el microambiente de la placa

Una vez retenidas en la íntima, las LDL sufren una modificación oxidativa por la mieloperoxidasa, la lipooxigenasa y las especies reactivas del oxígeno. LDL oxidada es reconocido por los receptores scavenger (CD36, SR-A) en células residentes y recién reclutadas macrófagos, que lo internalizan y se convierten células espumosas. En las lesiones subclínicas tempranas, la muerte de las células espumosas se equilibra con efrocitosis — la eliminación de células apoptóticas por los macrófagos vecinos —, pero a medida que el microentorno se vuelve cada vez más tóxico, la eferocitosis falla, los restos apoptóticos y necróticos se acumulan, y un núcleo necrótico formas. Las células de músculo liso vascular (VSMC) cambian simultáneamente de un fenotipo contráctil a uno sintético, migrando de la túnica media a la íntima, donde secretan una matriz rica en colágeno cápsula fibrosa que inicialmente estabiliza la lesión. El equilibrio entre la reparación que engrosa la capa fibrosa y la inflamación que expande el núcleo determina si una placa permanece estable o progresa hacia la vulnerabilidad82], [83], [84].

5. Disfunción endotelial como la lesión detectable más temprana

La disfunción endotelial precede a cualquier lesión estructural detectable por grosor íntima-media carotídeo (GIMC), la puntuación de calcio en las arterias coronarias o la angiografía. Es funcional, dinámica y parcialmente reversible, y por lo tanto representa la ventana práctica más temprana para la intervención primordial.

Dilatación mediada por flujo

Braquial dilatación mediada por flujo (DMF), medidos por ultrasonido después de un manguito en el antebrazo de 5 minutos oclusión, cuantifica la vasodilatación dependiente del endotelio (en gran medida mediada por óxido nítrico). Una FMD más baja se asocia con un mayor riesgo cardiovascular, pero la FMD depende del protocolo y ningún punto de corte universal único se aplica en todos los laboratorios; los valores por debajo de aproximadamente 5 a 7 por ciento se consideran comúnmente anormales en contextos de investigación. En el Estudio Multiétnico de Aterosclerosis (MESA), la FMD aportó información pronóstica independiente más allá del riesgo de Framingham y el IMT-C [33]. La FMD está deteriorada en sujetos con niveles de LDL incluso levemente elevados, insulina resistencia, sin tratar hipertensión, o exposición crónica a la contaminación del aire por partículas.

5.2 Índice de hiperemia reactiva

El índice de hiperemia reactiva (RHI), medido de forma no invasiva mediante pletismografía digital (EndoPAT), refleja la microvascularización función endotelial en la yema del dedo después de la hiperemia reactiva. Se ha utilizado un umbral de RHI de alrededor de 1.67 para identificar la disfunción endotelial coronaria o la aterosclerosis coronaria temprana en cohortes seleccionadas; la sensibilidad y la especificidad dependen de la población y del estándar de referencia [34]. RHI es independiente del operador, tiene buena reproducibilidad y se ha utilizado como resultado en ensayos de intervención farmacológica y en el estilo de vida.

5.3 Degradación del glucocálix

El glicocáliz endotelial es una capa superficial de tipo gel de 0,5 a 3 μm compuesta de proteoglicanosheparán sulfato, sulfato de condroitina), glicoproteínas (sindecán-1) y plasma adsorbido proteínas. Modula la transcitosis de LDL, el rodamiento de leucocitos y la mecanotransducción por esfuerzo cortante. Glicocálix degradación impulsada por LDL oxidada, hiperglucemia, el TNF-α y las especies reactivas de oxígeno, expone moléculas de adhesión y aumenta el flujo de lipoproteínas en la íntima. El adelgazamiento del glucocáliz, detectable mediante imágenes sublinguales de campo oscuro lateral y por niveles elevados de syndecan-1 y hialuronano en plasma, ocurre antes de la alteración medible de la dilatación mediada por flujo (DMF) y se encuentra entre las primeras anomalías detectables en la enfermedad subclínica [35], [36].

5.4 Disfunción microvascular que precede a la enfermedad macrovascular

Reserva de flujo coronario (CFR) por debajo de 2.0 por tomografía por emisión de positrones, por debajo de 2.5 mediante Doppler transtorácico, o por debajo de 2.0 mediante resonancia magnética cardíaca es un predictor independiente de eventos cardiovasculares incluso en ausencia de enfermedad epicárdica obstructiva. La disfunción endotelial microvascular puede ocurrir con coronarias normales angiografías, proporcionando el sustrato para el síndrome de isquemia con no obstructiva arterias coronarias (INOCA), discutida en la Sección 8 [37].

6. Mapeo anatómico de la enfermedad vascular subclínica

La aterosclerosis es una enfermedad sistémica pero no uniforme, que favorece sitios anatómicos específicos caracterizados por una geometría compleja y un flujo alterado. El mapeo preciso en todos los lechos vasculares revela el patrón predecible y dependiente de la geometría de la localización de la placa.

6.1 Lechos cerebrovasculares y cervicales

En el cuello, la bifurcación carotídea y la arteria carótida interna proximal son los sitios principales para el desarrollo temprano de placas, debido a la separación del flujo, la recirculación y la baja fricción oscilatoria en el bulbo carotídeo. Dentro del cráneo, la enfermedad se observa con mayor frecuencia en la ACI intracraneal (sifón carotídeo) y en los segmentos proximales de las ramas principales del polígono de Willis. Las series de autopsias indican que la aterosclerosis intracraneal se retrasa con respecto a la enfermedad extracraneal por aproximadamente 15 a 20 años; las lesiones estables son más comunes en la ACI, mientras que las lesiones más dinámicas y progresivas se encuentran en la ACM, la ACA y las arterias cerebrales posteriores.

Es importante destacar que, enfermedad aterosclerótica intracraneal representa aproximadamente el 9 por ciento de golpes en poblaciones blancas, pero del 30 al 50 por ciento de los accidentes cerebrovasculares en poblaciones de Asia oriental, negras e hispanas [73], [74]. Esta disparidad racial persiste tras el ajuste por las variables tradicionales factores de riesgo, lo que sugiere contribuciones genéticas y estructurales subyacentes. El ensayo SAMMPRIS estableció que el manejo médico es superior a la colocación de un stent para la enfermedad intracraneal aterosclerótica sintomática con una estenosis del ≥70 por ciento [73].

6.2 Coronary Vasculature and Aorta

Coronary atherosclerosis typically initiates in the proximal segments of the epicardial arteries, with the proximal LAD showing the highest plaque prevalence — particularly within the first 40 mm — owing to its acute take-off angle and the high flow disturbance generated at the bifurcations of diagonal and septal branches. Bifurcations of the LAD with diagonals, the LCx with obtuse marginals, and the RCA with the posterior descending artery all show predilection at the lateral, low-shear walls of the side branches.

The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study confirmed that estrías grasas and raised lesions are present in the coronaries of individuals as young as 15–34 years. In the aorta, a clear gradient of susceptibility exists: the abdominal aorta is more severely affected than the thoracic aorta, with the highest concentration of plaques occurring in the distal abdominal aorta and at the aortic bifurcation.

6.3 Renal and Mesenteric Arteries

Atherosclerotic renal artery stenosis (ARAS) accounts for approximately 90 percent of renal artery stenosis cases and primarily involves the renal artery ostia and the proximal 2 cm of the main renal artery. By contrast, fibromuscular dysplasia, which accounts for the remaining ≈10 percent, typically affects the middle and distal segments or intrarenal branches. Mesenteric artery disease — involving the celiac trunk and the superior and inferior mesenteric arteries — also occurs most often at the aortic origins, where flow turbulence is greatest.

6.4 Lower Extremity and Pelvic Arteries

Peripheral arterial disease follows a predictable progression from elastic to muscular arteries. Atherosclerosis typically appears first in the suprainguinal elastic arteries (aorta and iliacs) before progressing to the infrainguinal muscular arteries (femoral, popliteal, and tibial). Pelvic vascular disease frequently involves the internal pudendal artery (IPA), where significant stenosis or occlusion has been documented in approximately 54 percent of men screened for enfermedad de las arterias coronarias — an extraordinary prevalence reflecting the small caliber and shared risk-factor exposure of these vessels. The distal branches of the IPA, including the cavernosal arteries, are uniquely susceptible because of their small diameter (0.5–1 mm), as discussed in Section 9.

7. Differentiation of Large-Artery Atherosclerosis and Cerebral Small Vessel Disease

The distinction between classic atherosclerosis and cerebral small vessel disease (cSVD) is fundamental to understanding the divergent mechanisms of vascular injury across the human body.

7.1 Why Penetrating Arterioles Do Not Develop Classic Atherosclerosis

The penetrating arterioles (40–200 μm in diameter) that supply the deep brain — basal ganglia, thalamus, internal capsule, and periventricular white matter — do not exhibit the eccentric, lipid-rich plaques typical of large-vessel atherosclerosis. Three structural and biological factors explain this divergence:

First, structural simplicity: these vessels lack the multi-layered lamellar structure and the well-defined internal and external elastic laminae that support classic plaque architecture. Second, barrera hematoencefálica specialization: the células endoteliales of these vessels are specialized components of the neurovascular unit, with tight junctions formed by claudin-5, occludin, and ZO-1, supported by pericytes, astrocyte end-feet, and a unique metabolic environment that differs fundamentally from systemic vessels. Third, the absence of vasa vasorum: these vessels rely entirely on luminal and external diffusion and do not possess the intrinsic microvascular network that can be co-opted for plaque nourishment in larger arteries.

7.2 The Spectrum of Small Vessel Pathology

Instead of classic atherosclerosis, penetrating arterioles develop a distinct set of pathologies collectively termed cerebral small vessel disease. Lipohyalinosis, originally characterized by C. Miller Fisher as “segmental arteriolar wall disorganization,” involves accumulation of waxy, glassy lipid and protein aggregates within the vessel wall, fibrinoid necrosis of medial smooth-muscle cells, and luminal narrowing. It is driven primarily by chronic hypertension and is the principal substrate of lacunar infarcts in the lenticulostriate, thalamoperforating, and pontine penetrating arterioles.

Hyperplastic arteriolosclerosis involves concentric “onion-skin” thickening of the wall due to smooth-muscle proliferation and basement-membrane duplication and is more characteristic of malignant or accelerated hypertension. Microatheroma refers to occlusive lesions in larger penetrating vessels (200–800 μm); these share some features with atherosclerosis (foam cells, lipid retention) but typically occur at the proximal origin of the perforator and reflect the spillover of large-artery disease into branches.

Cerebral amyloid angiopathy (CAA) involves progressive deposition of β-amyloid (Aβ) — predominantly Aβ40 and to a lesser extent Aβ42 — in the media and adventitia of cortical and leptomeningeal arterioles (typically <2 mm in caliber). CAA is independent of hypertension and is a major contributor to lobar microbleeds, superficial siderosis, and convexity subarachnoid hemorrhage [23], [24]. Pathologically advanced cSVD frequently shows a transition from endothelial dysfunction to BBB disruption: failure of the BBB allows toxic serum components — fibrinogen, IgG, complement — to extravasate into the brain, triggering perivascular inflammation, “forced dilatation,” and connective-tissue accumulation that leaves downstream vessels vulnerable to high-pressure damage.

8. Early-Life Evidence and Longitudinal Risk Trajectories

8.1 Napoli/FELIC: Fetal Fatty Streaks

The earliest documented atherosclerotic lesion in humans is fetal. Napoli and colleagues, in the FELIC (Fate of Early Lesions in Children) study, demonstrated that fatty streaks form in the aortic intima of fetuses, with intimal accumulation of LDL and its oxidation preceding monocyte recruitment. Fetal fatty-streak formation was greatly enhanced by maternal hypercholesterolemia during pregnancy, suggesting that the maternal lipid environment programs offspring vascular vulnerability decades before clinical disease [52].

These observations transformed the conception of atherosclerosis from a disease of mid-life to a life-course disease initiated in utero, with the prenatal environment establishing the trajectory of subsequent intimal LDL accumulation.

8.2 PDAY and the Bogalusa Heart Study

El Estudio PDAY performed standardized autopsies on more than 3,000 individuals aged 15–34 who died of trauma, cataloguing the prevalence and extent of fatty streaks and raised lesions in the coronary arteries and aorta. Fatty streaks were present in essentially all aortas and in the coronaries of a majority by the late twenties; raised lesions appeared in approximately 20 percent of men aged 30–34. The study developed the PDAY risk score, which demonstrated that smoking, colesterol no HDL, and hypertension in youth are strong predictors of advanced calcification decades later.

El Estudio del corazón de Bogalusa extended these observations to a longitudinal community-based cohort, demonstrating that risk factors measured at ages 5–17 predict subclinical morbidity in adulthood. Berenson and colleagues, in autopsy data from 204 youths aged 2–39 who died of trauma, documented aortic fatty streaks in approximately half of children aged 2–15, rising to nearly 100 percent by age 21; coronary fatty streaks in 8 percent of children aged 2–15 and 69 percent of those aged 26–39; and coronary raised lesions in 3 percent of those aged 6–15 and 30 percent of those aged 26–39. The number of cardiovascular risk factors directly correlated with the extent of both fatty streaks and fibrous plaques [53].

8.3 The CARDIA Study

The Coronary Artery Risk Development in Young Adults (CARDIA) study followed 5,115 participants from ages 18–30 across more than 35 years of follow-up. Several findings have shaped contemporary preventive cardiology. First, sustained exposure to even modestly elevated LDL-C and presión arterial during the twenties and thirties contributes to ASCVD risk independently of risk levels later in life. Second, by Year 25 (mean age 50), approximately 27.7 percent of participants had detectable coronary artery calcium and approximately 53 percent had abdominal aortic calcium. Third, participants who adopted healthy habits — diet, exercise, smoking cessation, weight maintenance — during young adulthood had significantly less subclinical disease in middle age, with absolute reductions in event risk substantially larger than what mid-life intervention can achieve.

8.4 Pediatric and Adolescent Atherosclerosis: Familial Hypercholesterolemia

Heterozygous familial hypercholesterolemia (HeFH; prevalence ≈1:250) presents with LDL-C of 190–400 mg/dL from birth, the result of pathogenic variants en LDLR, APOB, or rarely PCSK9. Untreated, HeFH carries an approximately 50 percent CHD risk by age 50 in men. CIMT is significantly elevated in HeFH children by age 8–10. The landmark trial by Wiegman and colleagues demonstrated that statin initiation between ages 8 and 18 normalized CIMT progression compared with peers [54]. The 20-year follow-up of that cohort (Luirink and colleagues) showed that early statin treatment reduced MI risk by approximately 75 percent compared with untreated parents — among the strongest demonstrations in any field of medicine that early, sustained intervention can fundamentally alter a genetically determined disease trajectory [55].

9. Functional Impact of Subclinical Vascular Disease in Young and Middle-Aged Adults

Subclinical atherosclerosis is often described as “silent,” yet rigorous research demonstrates measurable functional deficits well before traditional clinical thresholds are reached.

9.1 Cognitive Function and Neurovascular Decay

In the CARDIA cohort, higher levels of CAC and abdominal aortic calcium at ages 43–55 were significantly associated with worse scores on tests of psychomotor speed (Digit Symbol Substitution Test), sustained attention, and verbal memory. This relationship persists after adjustment for age, sex, education, and traditional risk factors, suggesting that advanced calcified lesions in mid-life reflect a lifetime of vascular stress that also affects the brain microvasculature and white-matter integrity. Intelligence at age 19 has been found to inversely correlate with carotid plaque status at age 60, an association likely mediated by the long-term influence of cognitive ability on socioeconomic status, healthcare access, and adherencia to healthy lifestyles.

9.2 Aerobic Capacity and Exercise Tolerance

The relationship between physical activity and subclinical disease is bidirectional. High condición cardiorrespiratoria in young adulthood protects against the development of CAC and increased CIMT 15 to 25 years later. Conversely, the presence of subclinical atherosclerosis subtly impairs exercise tolerance: subclinical disease reduces vascular reserve — the ability of arteries to dilate and increase flow during peak exertion — contributing to earlier fatigue and reduced V̇O₂ peak. Individuals with low cardiorespiratory fitness are two to three times more likely to die prematurely from ASCVD even when matched for traditional risk factors.

9.3 Sleep, Fatigue, and Mood

Extreme sleep durations (<6 or >8 hours) and poor subjective sleep quality are associated with increased CAC prevalence and higher pulse-wave velocity. Sleep-duration irregularity — variation greater than 120 minutes across a week — is linked to a 33 percent higher prevalence of high CAC burden. Circadian misalignment drives chronic low-grade inflammation and sympathetic nervous system activation, predisposing individuals to subclinical atherosclerosis. Although direct causal links to mood disorders are still emerging, the combination of vascular-driven fatigue, impaired sleep, and chronic inflammation contributes to reduced quality of life.

9.4 Erectile Dysfunction as a Sentinel Event: The Artery-Size Hypothesis

Erectile dysfunction (ED) is often the first clinical manifestation of systemic vascular disease. The internal pudendal artery (1–2 mm) and its cavernosal branches (0.5–1 mm) are markedly smaller than the proximal coronary arteries (3–4 mm), the internal carotid (5–7 mm), or the femoral artery (6–8 mm). According to the artery-size hypothesis articulated by Montorsi and colleagues, equivalent atherosclerotic carga de placa produces hemodynamically significant stenosis in small vessels first, so the cavernosal circulation reaches the threshold for symptomatic compromise years before the coronary circulation does [80].

Men with vascular ED have a markedly higher prevalence of subclinical CAD; the COBRA trial reported that vasculogenic ED preceded the symptomatic onset of CAD by a mean of approximately 3 years (range 2 to 5 years) [80]. This temporal relationship makes ED a clinically actionable sentinel: every man presenting with vasculogenic ED warrants formal cardiovascular risk assessment, often including CAC scoring, lipid profiling with apoB and Lp(a), and consideration of antiplatelet and lipid-lowering therapy.

9.5 Renal Function and Renal Reserve

In young, non-hypertensive adults, renal function (estimated filtración glomerular rate, eGFR) is independently associated with rigidez arterial measured by brachial-ankle pulse wave velocity (baPWV). Mediation analysis indicates that eGFR mediates the relationship between both systolic and diastolic blood pressure and subclinical atherosclerosis, particularly in males, suggesting that elevated blood pressure influences cardiovascular health partly through early reduction in renal reserve, with secondary endocrine and oxidative changes that accelerate atherosclerotic progression.

10. Sex-Specific Differences in Subclinical Atherosclerosis

Cardiovascular disease has historically been studied in male-predominant cohorts, and the recognition of distinct female phenotypes has lagged the corresponding biology by decades. Several mechanisms produce sex-specific differences in subclinical disease.

10.1 Coronary Microvascular Dysfunction

Women are disproportionately affected by coronary microvascular dysfunction (CMD), which is the dominant mechanism of ischemia in 50–60 percent of women with angina and non-obstructive coronary arteries. The Women’s Ischemia Syndrome Evaluation (WISE) study established CMD as a major sex-specific subclinical phenotype with prognostic implications equivalent to obstructive CAD [38].

10.2 INOCA and MINOCA

Ischemia with non-obstructive coronary arteries (INOCA) refers to symptomatic ischemia in the presence of <50 percent coronary stenosis; approximately 70 percent of patients are women. MI with non-obstructive coronary arteries (MINOCA) refers to MI with <50 percent stenosis, accounts for 5–15 percent of all MIs, and is two to three times more common in women than men. Mechanisms include disfunción microvascular, plaque erosion (rather than rupture), epicardial vasospasm, and spontaneous coronary artery dissection. Diagnosis requires invasive coronary functional testing — acetylcholine provocation, adenosine-induced flow reserve, and intravascular imaging — modalities still inconsistently available outside specialized centers [39].

10.3 Pregnancy as a Vascular Stress Test

Adverse pregnancy outcomes — preeclampsia, gestational hypertension, diabetes gestacional, preterm delivery — confer a 2- to 4-fold lifetime increase in cardiovascular events. Pregnancy is now recognized as a “physiological prueba de estrés” that exposes latent vascular and metabolic dysfunction; preeclampsia in particular is associated with elevated CIMT, increased PWV, and altered endothelial function years to decades after the index pregnancy [40]. A 2020 American Heart Association scientific statement recommends incorporating pregnancy history into routine cardiovascular risk assessment for women.

10.4 Menopause Transition and Accelerated Subclinical Progression

The Study of Women’s Health Across the Nation (SWAN) demonstrated accelerated CIMT progression and arterial stiffening across the late perimenopause and early postmenopause, with median CIMT progression approximately doubling in the year before to year after the final menstrual period. Estrógeno withdrawal removes its tonic effects on lipid metabolism, endothelial function, and vascular smooth-muscle phenotype. The SWAN findings have driven the recognition that the menopausia transition is a vulnerable window for prevención primaria rather than a static post-event endpoint [41].

10.5 Spontaneous Coronary Artery Dissection

Spontaneous coronary artery dissection (SCAD) is responsible for a disproportionate share of síndromes coronarios agudos in young women: more than 90 percent of SCAD cases occur in women, particularly in the peripartum period and in those aged 40–55. Approximately half of SCAD patients have coexisting fibromuscular dysplasia. SCAD is non-atherosclerotic, but its identification has reshaped the differential diagnosis of MI in young women [42].

Phenotype	Female-predominant?	Mechanism	Detection
INOCA	Yes (~70%)	Microvascular dysfunction; vasospasm	Acetylcholine provocation; CFR
MINOCA	Yes (2–3×)	Plaque erosion; SCAD; vasospasm	OCT; IVUS
SCAD	Yes (>90%)	Intramural hematoma in coronary wall	Coronary angio + OCT
Preeclampsia legacy	Female-only	Endothelial sensitization; HTN risk	Lifetime BP; CIMT
Menopause-accelerated CIMT	Sí	Estrogen withdrawal	Serial CIMT; PWV

Tabla 3. Female-predominant subclinical and clinical phenotypes of cardiovascular disease. CFR, coronary flow reserve; OCT, tomografía de coherencia óptica; IVUS, ecografía intravascular; SCAD, spontaneous coronary artery dissection; CIMT, carotid grosor íntima-media; PWV, pulse wave velocity.

11. The Vascular–Neurodegenerative Interface: Atherosclerosis and Alzheimer’s Disease

The historical binary distinction between vascular dementia and Alzheimer’s disease (AD) is increasingly untenable. Vascular factors — both large-vessel atherosclerosis and small vessel disease — are now recognized as central contributors to the development and trajectory of AD pathology, and a substantial fraction of clinically diagnosed AD has mixed vascular and neurodegenerative pathology at autopsy.

11.1 Oligemia and Amyloid Clearance

Severe atherosclerosis of the circle of Willis is significantly more prevalent in AD brains than in age-matched controls. Reduced cerebral perfusion — “oligemia” rather than frank ischemia — facilitates accumulation of β-amyloid (Aβ) by both increasing its production and impairing its clearance through perivascular and glymphatic pathways. Aβ itself is vasoactive, producing constriction of cerebral arteries and further aggravating the oligemic state in a self-reinforcing cycle of neurovascular decay.

11.2 Blood–Brain Barrier and Hippocampal Damage

Recent work has documented that systemic atherosclerosis is associated with amyloid and tau pathology mediated by BBB dysfunction in the hippocampus [23]. Vascular damage produces endothelial and smooth-muscle apoptosis, exacerbating cerebral amyloid angiopathy and promoting perivascular tau accumulation. Macrophages within atherosclerotic plaques can process platelet-derived amyloid precursor protein into Aβ40 and Aβ42, providing a direct biological link between systemic ApoB-driven atherosclerosis and neurodegenerative disease.

12. Inflammation in Subclinical Atherogenesis

12.1 hs-CRP and Residual Inflammatory Risk

Proteína C reactiva de alta sensibilidad (PCR-as) integrates upstream interleukin-6 signaling and has been validated as an predictor independiente of vascular events in Júpiter and multiple subsequent trials [28]. In statin-treated patients, “riesgo inflamatorio residual” — defined as hs-CRP ≥2 mg/L despite LDL <70 mg/dL — remains a powerful predictor of recurrent events; in many secondary-prevention cohorts, residual inflammatory risk now exceeds residual colesterol risk in magnitude [29].

12.2 The IL-1β / IL-6 Axis: CANTOS

El Canakinumab Anti-Inflammatory Trombosis Outcome Study (CANTOS) provided randomized evidence that targeting inflammation in the absence of any LDL-lowering effect can reduce cardiovascular events. Canakinumab — a monoclonal antibody against IL-1β — reduced the primary eventos cardiovasculares adversos mayores (MACE) endpoint by approximately 15 percent at the 150 mg dose without lowering LDL-C, with the greatest benefit in those with the largest reduction in IL-6 [30]. The trial supports the conclusion that inflammatory signaling contributes to recurrent events through mechanisms not fully captured by LDL-C reduction alone, and it identifies the inflamasoma NLRP3 → IL-1β → IL-6 → CRP axis as a clinically tractable therapeutic target. Atherosclerosis is now best framed as a disease driven by parallel and partially independent processes — apoB-particle retention and innate immune activation — both of which can be addressed for optimal event reduction.

12.3 Clonal Hematopoiesis of Indeterminate Potential

Clonal hematopoiesis of indeterminate potential (CHIP) refers to the presence of acquired somatic mutations in hematopoietic stem cells — most commonly in DNMT3A, TET2, ASXL1, and JAK2 — without overt hematologic malignancy. CHIP is detectable in fewer than 1 percent of young adults but in approximately 10 percent of individuals over age 70. Jaiswal and colleagues demonstrated that CHIP carriers have approximately 2-fold increased risk of coronary heart disease and earlier MI (by 5–10 years) [31]. Mechanistically, mutant myeloid cells secrete excess IL-1β and IL-6, accelerating vascular inflammation; consistent with this, several studies have reported greater subclinical atherosclerotic burden or progression in CHIP carriers, although effect sizes vary by mutation, cohort, and imaging endpoint. CHIP represents a major emerging axis of cardiovascular risk that is not detected by traditional risk-factor measurement.

12.4 Neutrophil-to-Lymphocyte Ratio

The neutrophil-to-lymphocyte ratio (NLR), readily computable from any complete blood count, is an inexpensive marker of systemic inflammation. Reviews and meta-analyses associate higher NLR with increased cardiovascular risk and accelerated subclinical atherosclerosis, but cutoffs vary by population and clinical setting; the commonly cited NLR threshold of >3.0 is best presented as a research-context cutoff rather than as a guideline-endorsed diagnostic threshold [32].

13. Lipoprotein(a) as an Independent Causal Risk Factor

13.1 Genetic and Mendelian Evidence

Lipoprotein(a) [Lp(a)] is predominantly genetically determined by variation at the LPA locus on chromosome 6q26-q27. The Copenhagen General Population Study demonstrated a stepwise dose-response relationship between LPA kringle IV-2 copy-number variation and myocardial infarction risk; Mendelian-randomization studies have confirmed causality with effect sizes greater per unit than those of LDL-C [20], [21], [27].

13.2 Mechanisms of Pathogenicity

Lp(a) consists of an LDL-like particle (one apoB-100 molecule, cholesterol, phospholipids) covalently linked via a single disulfide bond between Cys4326 of apoB and Cys4057 of apolipoprotein(a) [apo(a)]. Apo(a) is structurally homologous to plasminógeno, possessing 10 kringle IV repeats and a single kringle V domain, but lacks proteolytic activity. Multiple mechanisms of pathogenicity converge:

First, Lp(a) is the principal carrier of oxidized phospholipids on apoB lipoproteins; approximately 85 percent of plasma OxPL associated with apoB are bound to Lp(a). OxPL activate endothelial cells, monocytes, and plaquetas [22]. Second, the kringle IV-10 lysine-binding site of apo(a) competes with plasminogen for fibrin, impairing fibrinolisis and rendering Lp(a) prothrombotic [23]. Third, Lp(a) induces IL-6, IL-8, and MCP-1 expression in vascular cells, contributing to the pro-inflammatory phenotype. Fourth, Lp(a) is associated with calcific válvula aórtica stenosis, with Mendelian-randomization data establishing a causal link [24].

13.3 Prevalence and Clinical Implications

Approximately 20 percent of the global population has Lp(a) >50 mg/dL (>125 nmol/L), the threshold above which cardiovascular risk is materially elevated; approximately 1 in 5 individuals with premature MI have elevated Lp(a) [25], [26]. Distribution differs by ancestry: highest in West Africans, intermediate in Europeans, and lowest in East Asians.

Elevated Lp(a) should be treated as an independent causal risk factor that can coexist with absent, mild, or advanced coronary artery calcium. In MESA and the Dallas Heart Study, elevated Lp(a) and CAC were each independently associated with ASCVD risk, and participants with both elevated Lp(a) and CAC ≥100 had the highest observed risk [87]. Once-in-a-lifetime Lp(a) measurement is now supported by contemporary EAS/ESC guidance and by the 2024 National Lipid Association focused update on Lp(a) in clinical practice [25], [86]. Subclinical disease evaluation should include consideration of Lp(a)-driven phenotypes when CAC, plaque burden, aortic valve calcification, or events occur out of proportion to traditional risk factors. Emerging therapeutics — antisense oligonucleotides (pelar carne) and siRNA agents targeting LPA mRNA — can lower Lp(a) by 80–98 percent and are currently in phase 3 cardiovascular outcome trials.

14. Microvascular Contributions and Capillary Rarefaction

14.1 Capillary Density Loss in Hypertension

Capillary rarefaction — a reduction in the number of perfused capillaries per unit tissue volume — is a hallmark of essential hypertension and precedes the development of fixed BP elevation. Antonios and colleagues demonstrated approximately 14 percent reduction in dorsal-finger densidad capilar in hypertensives versus normotensives [56]. Rarefaction increases peripheral vascular resistance and contributes to organ dysfunction across the kidneys, retina, and heart.

14.2 Coronary Microvascular Dysfunction

Coronary microvascular dysfunction (CMD) affects approximately half of women with chest pain and a quarter of men. Diagnosis is based on PET-derived coronary flow reserve <2.0 or invasively measured index of microcirculatory resistance (IMR) >25. The long-term prognosis is sobering: even in the absence of obstructive epicardial disease, CMD doubles the risk of MACE. The ISCHEMIA trial substudy and the WISE-CVD continuation studies have established CMD as a clinically important entity [37], [38].

14.3 Retinal Microvasculature as a Window

Retinal arteriolar narrowing — quantified by lower arteriole-to-venule ratio on fundoscopy or by optical coherence tomography angiography — predicts cardiovascular events independently of traditional risk factors. The retina is the only vascular bed directly visualizable in vivo and provides a non-invasive read-out of systemic microvascular health [57].

15. Mechanisms of Asymptomatic Progression: Glagov Remodeling and Vulnerable Plaque

15.1 Outward Remodeling and the Glagov Phenomenon

Glagov and colleagues, in 1987, demonstrated that human coronary arteries undergo a two-stage remodeling process in response to plaque accumulation. In the compensatory phase, while plaque area remains less than approximately 40 percent of the area bounded by the internal elastic lamina, the total vessel area increases such that the lumen area remains approximately constant or even slightly increases [77]. Esto remodelación exterior allows substantial plaque burden to coexist with no restriction of resting blood flow — and thus no symptoms and no abnormality on standard luminography. Only in the encroachment phase, when plaque area exceeds ≈40 percent of the IEL area, does the vessel become unable to expand further, and the lumen begins to narrow rapidly. This biology explains why coronary angiography systematically underestimates plaque burden and why a single negative coronary angiogram does not exclude clinically meaningful subclinical disease.

15.2 Flow Reserve and Collateralization

The cardiovascular system possesses substantial functional reserve. In the coronary and renal beds, resting blood flow is typically maintained until stenosis exceeds 60–70 percent of luminal diameter; in skeletal-muscle beds, flow reserves are even higher. Slow progression of subclinical disease often allows the development of circulación colateral — alternative vascular pathways that bypass obstructive lesions — further masking the primary disease and contributing to the asymptomatic course.

15.3 The Vulnerable Plaque Concept

Not all plaques are equally dangerous. The Virmani–Stary classification defined the “fibroateroma de capa fina” (TCFA) as a plaque with a fibrous cap thinner than 65 μm overlying a large núcleo necrótico rico en lípidos (>10 percent of volumen de placa), with macrophage infiltration of the cap, intraplaque hemorrhage, and positive (outward) remodeling [81], [82]. The PROSPECT trial used three-vessel intravascular ultrasound with virtual histology to characterize 697 patients with acute coronary syndromes and showed that lesiones culpables of subsequent events were predominantly TCFAs with plaque burden ≥70 percent and minimum lumen area ≤4.0 mm² [72].

Característica	Threshold	cociente de riesgos instantáneos for MACE
Fibrous cap thickness	<65 μm (TCFA)	≈5–7×
Necrotic core volume	>10% of plaque volume	≈2–3×
Plaque burden	≥70% cross-section	≈5× (PROSPECT)
Minimum lumen area (IVUS)	≤4.0 mm²	≈3×
Positive remodeling index	≥1.10	≈2.5×
Placa de baja atenuación (CCTA)	<30 HU	≈2.5–3×
Napkin-ring sign (CCTA)	Qualitative	≈5×

Tabla 4. Vulnerable-plaque features and approximate hazard ratios for major adverse cardiovascular events. Ranges synthesized from PROSPECT, ICONIC, SCOT-HEART, and CRISP-CT data [63], [64], [65], [67], [72].

16. Pulse Wave Velocity, Arterial Stiffness, and Vascular Calcification

16.1 Two Distinct Calcification Phenotypes

Vascular calcification is not monolithic. Two distinct phenotypes coexist with different mechanisms, prognoses, and therapeutic implications. Intimal calcification occurs within lipid-rich atherosclerotic plaques and is the substrate quantified by the Agatston-method puntuación de calcio en las arterias coronarias; it is apoB-driven and predicts events. Medial calcification, classically described by Mönckeberg, occurs within the tunica media independently of lipids and is driven by osteogenic transdifferentiation of vascular smooth-muscle cells; it is most prominent in enfermedad renal crónica, tipo 2 diabetes, and aging [58].

16.2 Elastin Fragmentation

Aortic elastina has a half-life of approximately 70 years and is essentially non-renewable in the adult vasculature. Cyclic mechanical stress, MMP-2/MMP-9 activity, and elastolytic enzymes such as cathepsins S and K cause elastin fragmentation that directly increases pulse wave velocity. Loss of elastin recoil shifts mechanical load to collagen — a fiber 100 to 1000 times stiffer than elastin — producing the progressive aortic stiffening characteristic of envejecimiento vascular.

16.3 Calcium-Phosphate Crystallization

In CKD, hyperphosphatemia drives VSMC apoptosis and matrix-vesicle release, which nucleate hydroxyapatite crystals. Pyrophosphate, fetuin-A, and matrix Gla protein are physiological inhibitors that decline with age and CKD. Klotho — a transmembrane and circulating protein expressed in kidney that serves as co-receptor for FGF23 — declines with age, and klotho deficiency directly accelerates vascular calcification. FGF23 itself is independently associated with hipertrofia ventricular izquierda, vascular calcification, and cardiovascular mortality [58], [59].

16.4 Pulse Wave Velocity Cutoffs

Pulse wave velocity, the gold-standard non-invasive measure of arterial stiffness, has well-established prognostic thresholds. Carotid–femoral PWV (cfPWV) is the gold standard; the European Society of Hypertension/European Society of Cardiology consensus document established >10 m/s as the threshold for elevated cardiovascular risk after correction for the actual travel path of the pulse wave [60]. Brachial–ankle PWV (baPWV), used predominantly in East Asian populations, has a commonly applied threshold of >14 m/s for elevated risk and >18 m/s for severe arterial stiffening [61].

16.5 Augmentation Index and CAVI

Augmentation index (AIx@75), derived from pulse wave analysis, reflects wave reflection from the periphery and is elevated in arterial stiffening; thresholds >25 percent are associated with elevated risk [60]. The cardio-ankle vascular index (CAVI) is a BP-independent measure of arterial stiffness, with values >9 indicating elevated risk [62].

17. Detection Modalities for Subclinical Vascular Disease

17.1 Coronary Artery Calcium Scoring

Non-contrast CT scanning of the heart with computation of the Puntaje de Agatston remains the most widely validated single test for subclinical coronary disease. CAC of zero in asymptomatic adults confers a very low 10-year MACE risk, and CAC is incorporated as a risk-decision tool in the 2018 AHA/ACC cholesterol guidelines and the 2019 ESC/EAS dislipidemia guidelines. The radiation dose is approximately 1 mSv, comparable to natural background exposure for several months.

17.2 Coronary CT Angiography and High-Risk Plaque Features

Angiografía por tomografía computarizada coronaria (CCTA) provides whole-vessel morphology and the ability to identify high-risk plaque features that are not captured by Agatston scoring alone. These features include low-attenuation plaque (<30 HU within plaque, indicating lipid-rich necrotic core; HR for MACE ≈2.5–3.0); positive remodeling (remodeling index ≥1.10); spotty calcification; and the napkin-ring sign (central low attenuation surrounded by a rim of higher attenuation; HR ≈5) [63], [64].

The five-year SCOT-HEART analysis demonstrated that CCTA-guided management reduced fatal and non-fatal MI by 41 percent compared with standard care in symptomatic patients [65]. The PROMISE and CONFIRM2 registries have provided further prognostic validation.

17.3 Pericoronary Fat Attenuation Index

Pericoronary fat attenuation index (FAI), introduced by Antonopoulos and colleagues, quantifies CT attenuation of pericoronary adipose tissue within a defined radial zone. Inflamed coronary segments shift the local adipose attenuation toward less negative HU values (less lipid, more aqueous), reflecting paracrine inflammatory signaling between coronary plaque and surrounding fat [66]. The CRISP-CT study demonstrated that elevated perivascular FAI predicts cardiac mortality independently of plaque burden, with the strongest signal observed for high FAI around the proximal right coronary artery [67]. FAI-derived metrics are now incorporated into commercial post-processing platforms; U.S. FDA clearance has been reported for some products in this family (e.g., CaRi-Plaque), while CaRi-Heart/FAI-Score has regulatory clearance in selected non-U.S. markets and remains in evolving regulatory status in the United States, so specific labeling claims should be verified by product and date.

17.4 AI-Quantitative CCTA

AI-enhanced and deep-learning quantitative coronary CT angiography (AI-QCT) — exemplified by the Cleerly and HeartFlow Plaque Analysis platforms — automates segmentation of total plaque volume; calcified, non-calcified, and low-attenuation components; remodeling indices; and pericoronary fat attenuation. A 2022 international multicenter study by Lin and colleagues validated a deep-learning CCTA pipeline against expert readers and demonstrated favorable reproducibility and prognostic performance for plaque, stenosis, and predicción de riesgos [88]. AI-QCT methods are increasingly used clinically, but specific platform claims should be matched to platform-specific validation data.

17.5 Vessel Wall MRI

High-resolution 3-Tesla vessel-wall MRI with black-blood sequences (DANTE-prepared T1, SPACE, MERGE) directly images the arterial wall, allowing differentiation of intracranial atherosclerosis (eccentric, peripheral enhancement) from vasculitis (concentric enhancement) and dissection (intramural hematoma). VW-MRI detects plaque before luminal narrowing and is particularly valuable in evaluating intracranial atherosclerotic disease [69].

17.6 Optical Coherence Tomography

Intravascular optical coherence tomography (OCT) provides 10-μm-resolution cross-sectional imaging of coronary plaques, capable of measuring fibrous cap thickness directly and identifying microcalcifications, plaque erosion, and intracoronary thrombus. OCT is the imaging modality of choice when characterizing plaque morphology in MINOCA and SCAD.

17.7 Ultrasound Microvascular Imaging

Contrast-enhanced ultrasound and super-resolution ultrasound localization microscopy (ULM) image vasa vasorum neovascularization within carotid plaques and detect microvascular rarefaction at micron-scale resolution, providing a functional read-out of plaque inflammation and tissue microcirculation [70].

17.8 Carotid Intima-Media Thickness, Ankle-Brachial Index, and Renal Doppler

Carotid intima-media thickness >0.9 mm (and focal IMT >1.5 mm defining plaque) on high-resolution B-mode ultrasound predicts cardiovascular events and is widely used in pediatric and FH research. Ankle-brachial index <0.9 indicates significant peripheral arterial disease and confers elevated cardiovascular risk irrespective of symptoms. Renal Doppler with peak systolic velocity >180–200 cm/s at the renal ostium and renal-aortic ratio >3.5 is the screening test of choice for renal artery stenosis.

Vascular bed	Preferred modality	Key parameter / threshold
Coronario	Non-contrast CT (Agatston)	CAC score >0 indicates subclinical disease
Coronario	CCTA	LAP, NRS, PR; FAI; AI-QCT plaque volumes
Carotid	Ultrasound	CIMT >0.9 mm; plaque defined as focal IMT >1.5 mm
Lower limb	Ankle-brachial index	ABI <0.9 indicates significant PAD
Brain (large)	Vessel-wall MRI	Eccentric wall thickening; contrast enhancement
Systemic	Pulse wave velocity	cfPWV >10 m/s; baPWV >14 m/s
Renal	Duplex ultrasound / MRA	PSV >180–200 cm/s; renoaortic ratio >3.5
Endotelial	Brachial FMD; EndoPAT RHI	FMD <7%; RHI <1.67

Table 5. Preferred imaging and physiological modalities for detection of subclinical vascular disease across the arterial tree. CAC, coronary artery calcium; CCTA, coronary CT angiography; LAP, low-attenuation plaque; NRS, napkin-ring sign; PR, positive remodeling; FAI, pericoronary fat attenuation index; AI-QCT, AI-quantitative coronary CT; CIMT, carotid intima-media thickness; PWV, pulse wave velocity; FMD, flow-mediated dilation; RHI, reactive hyperemia index.

18. Genetic Factors and Polygenic Risk

18.1 The 9p21 Locus

The chromosome 9p21.3 locus was identified by genome-wide association in 2007 as the first robustly replicated CHD susceptibility region. Each risk allele confers approximately 25 percent increased CHD risk, independent of all known traditional risk factors. The locus contains the long non-coding RNA ANRIL and lies adjacent to the CDKN2A/CDKN2B tumor-suppressor genes; the proposed mechanism involves dysregulation of vascular smooth-muscle proliferation and senescence [75].

18.2 LDLR, APOB, and PCSK9 Variants

Familial hypercholesterolemia is caused by pathogenic variants in LDLR (>2,000 mutations described), APOB (R3500Q the canonical variant of familial defective apoB), or, rarely, gain-of-function variants in PCSK9. The prevalence of heterozygous FH is approximately 1 in 250 in most populations; homozygous FH is roughly 1 in 300,000. Loss-of-function variants in PCSK9 (R46L, Y142X, C679X) reduce LDL across the life course and confer 30–88 percent reductions in CHD [12].

18.3 Polygenic Risk Scores

Khera and colleagues constructed a polygenic risk score comprising 6.6 million variants and demonstrated that the top 8 percent of the population have a 3-fold increased CHD risk — an effect equivalent in magnitude to monogenic FH. Polygenic scores add incremental prognostic information beyond traditional risk factors and Mendelian variants and are increasingly being incorporated into multi-layered risk-stratification models [76].

19. Lifestyle Reversibility and Plaque Regression: The Trial Evidence

A central question for the practicing clinician is whether subclinical atherosclerosis can be reversed once established. The available imaging-based randomized and case-series evidence supports the conclusion that, with sufficient reduction in apoB-particle exposure and inflammation, both functional and structural plaque regression is achievable.

19.1 The Lifestyle Heart Trial (Ornish)

The Lifestyle Heart Trial randomized 48 patients with angiographically documented CAD to a comprehensive lifestyle intervention or usual care. The intervention combined a whole-food plant-based (WFPB) diet (≈10 percent of calories from fat), ejercicio aeróbico, stress management with yoga and meditation, group support, and smoking cessation. Quantitative coronary angiography at 1 year showed mean percent estenosis de diámetro decreased from 40.0 percent to 37.8 percent in the experimental group versus an increase from 42.7 percent to 46.1 percent in controls (between-group p<0.001) [43]. At 5-year follow-up, the experimental group showed continued regression to 37.3 percent versus control progression to 51.9 percent, with approximately 2.5-fold fewer eventos cardíacos in the intervention group [44]. The Lifestyle Heart Trial is among the best-known randomized lifestyle interventions to demonstrate regresión angiográfica of coronary atherosclerosis.

19.2 The Esselstyn Case Series

Esselstyn and colleagues prospectively followed 198 consecutive self-selected patients with established CAD who adopted an oil-free WFPB diet. Of these, 177 (89.4 percent) were adherent over a mean 3.7 years of follow-up. Adherent patients experienced a 0.6 percent recurrent event rate, while non-adherent patients experienced a 62 percent event rate, and several patients showed angiographically documented coronary regression. The principal limitations are well recognized: the absence of a concurrent control group, self-selected participants, adherence-related selection effects, and reliance on chart-based outcome ascertainment. The findings are best presented as supportive and hypothesis-generating, consistent with the intensive lifestyle-trial evidence above, rather than as proof that WFPB intervention is uniquely effective [45].

19.3 STARS and the Heidelberg Trial

The St Thomas’ Atherosclerosis Regression Study (STARS) randomized 90 men with CAD to usual care, a lipid-lowering diet, or diet plus cholestyramine. Quantitative angiography at 39 months showed regression in 38 percent of the diet group, 33 percent of the diet + drug group, and only 4 percent of usual-care patients, with progression in 15 percent, 12 percent, and 46 percent respectively [46]. The Heidelberg Trial (Schuler and colleagues) demonstrated, with a multifactorial intervention combining a low-fat diet and structured exercise, reduced angiographic progression and modest regression at 1 year [47].

19.4 IVUS-Documented Statin and PCSK9-Inhibitor Regression Trials

Beginning with REVERSAL in 2004, intravascular ultrasound has provided high-resolution quantification of changes in volumen percentual de ateroma (PAV) y volumen total de ateroma (VTA) in response to lipid-lowering therapy. The cumulative dataset establishes a clear dose–response: progressively lower on-treatment LDL produces progressively greater plaque regression.

Trial	Año	Terapia	LDL achieved	Resultado
Lifestyle Heart	1990, 1998	WFPB + multimodal lifestyle	≈95 mg/dL	Stenosis −7.9% (relative); ~2.5× fewer events
Esselstyn series	1999, 2014	Oil-free WFPB diet	Variable; intensive LDL lowering	0.6% recurrent events in adherents over mean 3.7 yr; uncontrolled, self-selected
STARS	1992	Diet ± cholestyramine	≈125 mg/dL	38% regression vs. 4% usual care
REVERSIÓN	2004	Atorvastatina 80 mg	79 mg/dL	PAV stable (Δ −0.4%)
ASTEROIDE	2006	Rosuvastatina 40 mg	60.8 mg/dL	PAV −0.98%, TAV −6.8%
Saturno	2011	Rosuva 40 vs. atorva 80	62 / 70 mg/dL	PAV −1.22% / −0.99%
GLAGOV	2016	Evolocumab + statin	36.6 mg/dL	PAV −0.95% vs. +0.05%
PACMAN-AMI	2022	Alirocumab + statin	23.5 mg/dL	PAV −2.13%; ↑ fibrous cap thickness
Huygens	2022	Evolocumab + statin	28.1 mg/dL	Fibrous cap thickness +42.7 μm

Table 6. Imaging-verified plaque regression trials, organized by intervention intensity and on-treatment LDL-C. PAV, percent ateroma volume; TAV, total atheroma volume; WFPB, whole-food plant-based [14], [15], [16], [17], [43], [44], [45], [46], [48], [49].

REVERSAL demonstrated essentially halted progression at LDL ≈79 mg/dL with high-dose statin therapy [14]. ASTEROID was the first trial to demonstrate clear regression — PAV reduced by 0.98 percent and TAV reduced by 6.8 percent — at on-treatment LDL of 60.8 mg/dL with rosuvastatin 40 mg [15]. SATURN extended the comparison to include atorvastatin 80 mg [16]. GLAGOV randomized 968 patients on optimized statin therapy to evolocumab or placebo and demonstrated PAV regression of 0.95 percent in the evolocumab arm at on-treatment LDL of 36.6 mg/dL [17]. PACMAN-AMI, in patients post-acute MI, demonstrated PAV reduction of 2.13 percent and concurrent stabilization of plaque morphology — increased fibrous cap thickness, decreased lipid pool — at on-treatment LDL of 23.5 mg/dL with alirocumab on top of high-intensity statin [48]. HUYGENS, using OCT to measure fibrous-cap thickness directly, demonstrated an increase of 42.7 μm at on-treatment LDL of 28.1 mg/dL — converting many plaques from the TCFA to the thick-cap fibroateroma classification [49].

The combined message of these trials is that plaque regression and stabilization have been repeatedly observed with intensive LDL-C lowering, especially when achieved LDL-C is well below 70 mg/dL; the magnitude of regression varies by baseline plaque burden, imaging modality, achieved apoB/LDL-C, and background therapy.

19.5 The Subclinical Phase as the Optimal Intervention Window

Once a placa vulnerable has formed — with its necrotic core, thin fibrous cap, and positive remodeling — even aggressive therapy can reduce and stabilize risk but does not eliminate all residual events, even at very low achieved LDL-C [18]. Conversely, prevención primordial — preventing the first transcytosis–retention event by maintaining low apoB exposure across the life course — more closely approximates the large lifetime benefit observed in genetically lower-LDL states. The operational implication is direct: start early, lower sufficiently, and sustain risk-factor control indefinitely.

19.6 The CAC Paradox

Statin therapy has been observed to increase the volume of coronary calcium even while reducing event rates. This does not necessarily indicate harmful progression: statins can increase plaque calcium density (a marker associated with healing and stabilization) while reducing the lipid-rich, vulnerable component of plaque. Because the Agatston score weights calcium density (assigning higher scores to denser calcium), a stabilizing lesion may yield a higher Agatston score even as event risk falls. The CAC density and volume score, developed by Criqui and colleagues, addresses this paradox by demonstrating that, at any given total Agatston score, higher CAC density predicts fewer events [50], [51]. The clinical implication is that serial CAC scoring during statin therapy must be interpreted with reference to density and morphology, not the Agatston number alone.

20. Synthesis and Implications for Practice

Subclinical atherosclerosis is not a passive state of aging but an active, progressive biological syndrome with measurable consequences in early adulthood — and, increasingly, in childhood and even in utero. The body of evidence reviewed here supports several integrated conclusions.

First, atherogenesis is causally driven by apoB-containing lipoproteins. The convergence of Mendelian-randomization, familial-genetic, and randomized-trial evidence across approximately twenty independent lines of investigation establishes apoB causality with rigor unmatched in most areas of medicine. Risk is proportional to the integral of apoB-particle exposure over time. The corollary is that primordial prevention — maintaining low apoB across the life course — yields the largest possible event reduction.

Second, parallel non-lipid pathways amplify or modulate apoB-driven atherogenesis. Lp(a), inflammation (NLRP3 → IL-1β → IL-6 → CRP), clonal hematopoiesis, hypertension, glycemic dysregulation, and arterial stiffening each contribute mechanistically distinct components of risk. Comprehensive prevention addresses all of these axes, not LDL alone.

Third, the divergence between large-artery atherosclerosis and cerebral small vessel disease reflects a fundamental structural and hemodynamic threshold. Vessel-wall complexity and the presence of vasa vasorum permit lipid-core plaque formation; the simpler architecture of penetrating arterioles favors lipohyalinosis, microatheroma, and amyloid angiopathy instead. Each pathology has its own risk-factor profile and optimal therapeutic approach.

Fourth, the “clinical silence” of subclinical disease is maintained by adaptive remodeling — the Glagov phenomenon — and by physiological reserve in flow capacity. This silence is regularly punctured by subtle functional decays in cognitive processing speed, sleep regularity, exercise tolerance, and erectile function. These functional signals, properly recognized, provide a clinically actionable window for intervention years before the first overt event.

Fifth, sex-specific phenotypes — INOCA, MINOCA, SCAD, preeclampsia legacy effects, menopause-accelerated CIMT progression — have historically been under-diagnosed and require dedicated clinical pathways.

Sixth, the trial evidence — from the Lifestyle Heart Trial through the modern IVUS regression trials with inhibidores de la PCSK9 — supports the conclusion that subclinical atherosclerosis is, when addressed early and aggressively, partially reversible. Plaque can be stabilized, fibrous caps thickened, and event rates reduced. Whole-food plant-based dietary patterns and pharmacologic LDL-lowering both produce regression in their respective trial contexts; comprehensive lifestyle intervention complements rather than replaces appropriate pharmacologic therapy.

The life-course perspective provided by Napoli/FELIC, Bogalusa, PDAY, CARDIA, MESA, and the Tsimane natural experiment carries one practical message: the vascular integrity of late life is built on the risk exposures of youth. Early detection through CAC scoring, pulse wave velocity, vessel-wall MRI, FAI, and emerging AI-augmented imaging, combined with aggressive risk-factor management addressing apoB, Lp(a), inflammation, blood pressure, glycemia, sleep, fitness, and tobacco exposure, offers the realistic possibility of compressing cardiovascular morbidity to the very end of life. The goal of preventive cardiology is no longer the deferral of the first event by a decade; it is the elimination of clinical atherosclerotic disease as a routine cause of human suffering.

Referencias

1. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639. doi:10.1016/j.jacc.2012.09.017
2. Ference BA, Kastelein JJP, Catapano AL. Lipids and Lipoproteins in 2020. JAMA. 2020;324(6):595-596. doi:10.1001/jama.2020.5685
3. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375(22):2144-2153. doi:10.1056/NEJMoa1604304
4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
5. Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022;7(3):250-256. doi:10.1001/jamacardio.2021.5083
6. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
7. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322(14):1381-1391. doi:10.1001/jama.2019.14120
8. Vogel RA. The new cholesterol guidelines: finally more light than heat. J Am Coll Cardiol. 2014;64(9):920-921. doi:10.1016/j.jacc.2014.06.1168
9. Domanski MJ, Tian X, Wu CO, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020;76(13):1507-1516. doi:10.1016/j.jacc.2020.07.059
10. Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet. 2017;389(10080):1730-1739. doi:10.1016/S0140-6736(17)30752-3
11. Pontzer H, Wood BM, Raichlen DA. Hunter-gatherers as models in public health. Obes Rev. 2018;19 Suppl 1:24-35. doi:10.1111/obr.12785
12. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013
13. Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. J Am Coll Cardiol. 2017;69(16):2054-2063. doi:10.1016/j.jacc.2017.02.030
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080. doi:10.1001/jama.291.9.1071
15. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
16. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
17. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
18. Gaba P, O’Donoghue ML, Park JG, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023;147(16):1192-1203. doi:10.1161/CIRCULATIONAHA.122.063399
19. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. doi:10.1093/eurheartj/ehz962
20. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. doi:10.1001/jama.2009.801
21. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528. doi:10.1056/NEJMoa0902604
22. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi:10.1016/j.jacc.2016.11.042
23. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15(2):167-174. doi:10.1097/00041433-200404000-00009
24. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503-512. doi:10.1056/NEJMoa1109034
25. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361
26. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853. doi:10.1093/eurheartj/ehq386
27. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184. doi:10.1161/CIRCULATIONAHA.107.715698
28. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646
29. Ridker PM. How Common Is Residual Inflammatory Risk?. Circ Res. 2017;120(4):617-619. doi:10.1161/CIRCRESAHA.116.310527
30. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
31. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111-121. doi:10.1056/NEJMoa1701719
32. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):55-59. doi:10.1586/erc.12.159
33. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120(6):502-509. doi:10.1161/CIRCULATIONAHA.109.864801
34. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44(11):2137-2141. doi:10.1016/j.jacc.2004.08.062
35. van den Berg BM, Spaan JA, Rolf TM, Vink H. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol. 2006;290(2):H915-H920. doi:10.1152/ajpheart.00051.2005
36. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res. 2010;87(2):300-310. doi:10.1093/cvr/cvq137
37. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(21):2625-2641. doi:10.1016/j.jacc.2018.09.042
38. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(3 Suppl):S4-S20. doi:10.1016/j.jacc.2005.01.072
39. Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18):e891-e908. doi:10.1161/CIR.0000000000000670
40. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974. doi:10.1136/bmj.39335.385301.BE
41. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532. doi:10.1161/CIR.0000000000000912
42. Hayes SN, Kim ESH, Saw J, et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137(19):e523-e557. doi:10.1161/CIR.0000000000000564
43. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133. doi:10.1016/0140-6736(90)91656-u
44. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007. doi:10.1001/jama.280.23.2001
45. Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD?. J Fam Pract. 2014;63(7):356-364b.
46. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet. 1992;339(8793):563-569. doi:10.1016/0140-6736(92)90863-x
47. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992;86(1):1-11. doi:10.1161/01.cir.86.1.1
48. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
49. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002
50. Criqui MH, Denenberg JO, Ix JH, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311(3):271-278. doi:10.1001/jama.2013.282535
51. Henein M, Granåsen G, Wiklund U, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015;184:581-586. doi:10.1016/j.ijcard.2015.02.072
52. Napoli C, D’Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100(11):2680-2690. doi:10.1172/JCI119813
53. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650-1656. doi:10.1056/NEJM199806043382302
54. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331-337. doi:10.1001/jama.292.3.331
55. Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-1556. doi:10.1056/NEJMoa1816454
56. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension. 1999;34(4 Pt 1):655-658. doi:10.1161/01.hyp.34.4.655
57. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA. 2002;287(9):1153-1159. doi:10.1001/jama.287.9.1153
58. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938-2948. doi:10.1161/CIRCULATIONAHA.107.743161
59. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592. doi:10.1056/NEJMoa0706130
60. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445-448. doi:10.1097/HJH.0b013e32834fa8b0
61. Munakata M. Brachial-Ankle Pulse Wave Velocity: Background, Method, and Clinical Evidence. Pulse (Basel). 2016;3(3-4):195-204. doi:10.1159/000443740
62. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13(2):101-107. doi:10.5551/jat.13.101
63. Motoyama S, Ito H, Sarai M, et al. Plaque Characterization by Coronary Computed Tomography Angiography and the Likelihood of Acute Coronary Events in Mid-Term Follow-Up. J Am Coll Cardiol. 2015;66(4):337-346. doi:10.1016/j.jacc.2015.05.069
64. Maurovich-Horvat P, Ferencik M, Voros S, Merkely B, Hoffmann U. Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol. 2014;11(7):390-402. doi:10.1038/nrcardio.2014.60
65. SCOT-HEART Investigators, Newby DE, Adamson PD, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379(10):924-933. doi:10.1056/NEJMoa1805971
66. Antonopoulos AS, Sanna F, Sabharwal N, et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 2017;9(398):eaal2658. doi:10.1126/scitranslmed.aal2658
67. Oikonomou EK, Marwan M, Desai MY, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet. 2018;392(10151):929-939. doi:10.1016/S0140-6736(18)31114-0
68. Min JK, Leipsic J, Pencina MJ, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012;308(12):1237-1245. doi:10.1001/2012.jama.11274
69. Kang N, Qiao Y, Wasserman BA. Essentials for Interpreting Intracranial Vessel Wall MRI Results: State of the Art. Radiology. 2021;300(3):492-505. doi:10.1148/radiol.2021204096
70. Christensen-Jeffries K, Couture O, Dayton PA, et al. Super-resolution Ultrasound Imaging. Ultrasound Med Biol. 2020;46(4):865-891. doi:10.1016/j.ultrasmedbio.2019.11.013
71. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis. 1985;5(3):293-302. doi:10.1161/01.atv.5.3.293
72. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226-235. doi:10.1056/NEJMoa1002358
73. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003. doi:10.1056/NEJMoa1105335
74. Wang Y, Meng R, Liu G, et al. Intracranial atherosclerotic disease. Neurobiol Dis. 2019;124:118-132. doi:10.1016/j.nbd.2018.11.008
75. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491-1493. doi:10.1126/science.1142842
76. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224. doi:10.1038/s41588-018-0183-z
77. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
78. Wolinsky H, Glagov S. A lamellar unit of aortic medial structure and function in mammals. Circ Res. 1967;20(1):99-111. doi:10.1161/01.res.20.1.99
79. Okita Y. An intimal cylinder in the descending aorta. J Thorac Cardiovasc Surg. 2015;150(3):e35-e36. doi:10.1016/j.jtcvs.2015.06.043
80. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27(22):2632-2639. doi:10.1093/eurheartj/ehl142
81. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46(6):937-954. doi:10.1016/j.jacc.2005.03.074
82. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 Suppl):C13-C18. doi:10.1016/j.jacc.2005.10.065
83. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832-1844. doi:10.1161/CIRCULATIONAHA.106.676890
84. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695. doi:10.1056/NEJMra043430
85. Gimbrone MA Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118(4):620-636. doi:10.1161/CIRCRESAHA.115.306301
86. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. doi:10.1016/j.jacl.2024.03.001
87. Mehta A, Vasquez N, Ayers CR, et al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022;79(8):757-768. doi:10.1016/j.jacc.2021.11.058
88. Lin A, Manral N, McElhinney P, et al. Deep learning-enabled coronary CT angiography for plaque and stenosis quantification and cardiac risk prediction: an international multicentre study. Lancet Digit Health. 2022;4(4):e256-e265. doi:10.1016/S2589-7500(22)00022-X